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PVIEWPOINT
Nitrate-Induced Toxicity and Preconditioning
A Rationale for Reconsidering the Use of These Drugs
Tommaso Gori, MD, PHD,*† John D. Parker, MD, FACC‡
Siena, Italy; Mainz, Germany; and Toronto, Ontario, Canada
Although organic nitrates have been clinically used for more than a century, findings in the last decade have rad-
ically challenged our traditional view concerning the mechanism(s) of their clinical effects and implications.
While their hemodynamic properties are well known, the knowledge that nitrates possess previously unexpected
nonhemodynamic effects is a unique opportunity of which clinicians should be aware but, at the same time, it
also provides a rationale to worry about previously unanticipated clinical consequences of long-term treatment
with these drugs. (J Am Coll Cardiol 2008;52:251–4) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.019l
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Srganic nitrates are among the oldest and yet most com-
only used drugs in the chronic therapy of patients with
ngina and heart failure. Their use is based on 2 assump-
ions that remain, after decades of research, unproven. The
rst is an assumption of overall clinical safety: the majority
f physicians believe that chronic therapy with organic
itrates is associated with an improvement in symptoms and
as neutral or potentially beneficial effects on long-term
atient outcome. A corollary of this concept is that nitrate
olerance is considered simply as the loss of a beneficial
ffect as opposed to the expression of potentially deleterious
odifications such as sympathetic activation, increased
xidative stress, or endothelial dysfunction (discussed later).
he second assumption is that the therapeutic effects of
hese drugs depend exclusively on changes in hemodynamic
arameters (principally dilation of capacitance veins and
onduit arteries).
Recently, both of these postulates have come under
crutiny as recent lines of evidence document that organic
itrates have previously unanticipated nonhemodynamic
ffects. Importantly, these changes have dichotomous im-
lications, as confirmed by human in vivo studies. Some of
hese effects are protective (e.g., a protection that is similar
o ischemic preconditioning), but others are potentially
armful, including increased oxidative stress (1), endothelial
ysfunction (2), and cardiac autonomic dysfunction (3). In
rom the *Department of Internal, Cardiovascular, and Geriatric Medicine, Univer-
ity of Siena, Siena, Italy; †Medizinische Klinik, University of Mainz, Mainz,
ermany; and the ‡Division of Cardiology, Department of Medicine, Mount Sinai
nd University Health Network Hospitals, University of Toronto, Toronto, Ontario,
anada. Dr. Gori is the recipient of a grant from the Italian Ministry of Research. Dr.
arker holds a Career Investigator Award from the Heart and Stroke Foundation of
ntario, Canada.t
Manuscript received January 4, 2008; revised manuscript received March 26, 2008,
ccepted April 3, 2008.ight of continued widespread use, we believe that these
otions should be discussed, and that the traditional views
oncerning chronic therapy with organic nitrates should be
ritically revised.
Challenging the first of the postulates above, Münzel
t al. (1) reported in 1995 that the sustained administration
f nitroglycerin (glyceryl trinitrate) causes increased oxygen
ree radical bioavailability, a finding that led to the oxidative
tress hypothesis of nitrate tolerance (reviewed in Münzel
t al. [1], Gori and Parker [2], and Fig. 1). The accumula-
ion of oxygen free radicals during chronic nitroglycerin
herapy has been associated with endothelial dysfunction,
ith an increased arterial sensitivity to vasoconstrictors and
ith the development of abnormalities in a number of
mportant enzymes involved in the regulation of vascular
omeostasis, including the superoxide dismutase, protein
inase C, matrix metalloproteinases, and prostaglandin
ynthase (1,2). Furthermore, prolonged exposure to nitro-
lycerin has been shown to shift the physiologic balance
etween the sympathetic and vagal nervous systems in the
odulation of cardiac heart rate and heart rate variability
oward a prevalence of the sympathetic system, impairing
aroreflex function and heart rate variability (3). Of note,
uch modifications should be considered relevant because
hey have been associated with an increased incidence of
rrhythmias and a worse prognosis when observed in pa-
ients with coronary artery disease and/or heart failure (4).
wo observations emphasize the clinical importance of
hese findings. First, they have been observed (or repro-
uced) in patients with coronary artery disease: for instance,
itroglycerin therapy enhances coronary artery vasoconstric-
or responses to acetylcholine (5) and peripheral conduit
rterial responses to angiotensin II and phenylephrine (6).
econd, these deleterious effects are not limited to
olerance-inducing dosages: therapy with both nitroglyc-
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Chronic Therapy With Organic Nitrates July 22, 2008:251–4rin and isosorbide mononitrate, using formulations and
osing regimens that are commonly employed clinically,
ave also been shown to lead to the development of
ndothelial dysfunction (5,7). In aggregate, these vascular
bnormalities seem to play a major role in the develop-
ent of nitrate tolerance and the decreased anginal
hreshold observed in some patients during the daily
itrate-free interval (rebound angina [8]) (Fig. 1). Fur-
her, they suggest that we should not a priori assume that
he effects of nitrates in terms of patient prognosis are
ecessarily neutral, and emphasize the need for large-
cale trials testing the effects of long-term nitrate therapy.
Challenging the second of the postulates mentioned
arlier, organic nitrates have beneficial implications that go
ar beyond their impact on cardiac loading conditions. In
articular, intravenous or transdermal administration of
itroglycerin has been shown to trigger a protective pheno-
ype that is similar to that induced by ischemic pre-
onditioning and persists up to 48 to 72 h after interruption
f nitrate therapy: a single 2- to 4-h application of nitro-
Figure 1 Nitrate-Induced Nonhemodynamic Effects
Schematic representation of nitrate effects as shown in human studies. Prolonged
tolerance. A unifying hypothesis for an oxidative stress–based physiopathology of
causes modifications that might alter vascular homeostasis. One single administra
EPC  endothelial progenitor cell; NO  nitric oxide; ROS  reactive oxygen specilycerin protects the vascular endothelium from experimen- fal ischemia and reperfusion injury in healthy volunteers (9),
nd it has been associated with reduced electrocardiographic
nd echocardiographic evidence of ischemia during both
oronary angioplasty and physical exercise in ischemic heart
isease patients (10,11). Surprisingly, this nonhemody-
amic property of nitrates seems to be mediated by release
f oxygen free radicals, because administration of antioxi-
ants blocks it (9). Because ischemic preconditioning (and
ts clinical correlate, pre-infarction angina) have been shown
o be important determinants of patient prognosis (12), the
ossibility that such a protective state could be induced
harmacologically using “atypical” dosing regimens (for
nstance by administering nitrates for 2 to 4 h per day in
atients at high risk of coronary events) has a clinical
otential that deserves being tested in large-scale trials.
Recent experimental findings provide some insight into
he mechanism(s) of these unexpected effects (Fig. 2) and
ave important implications regarding how nitrates should
e used. The evidence of a beneficial preconditioning effect
f nitrates suggests that we should develop a new conceptual
termittent administration causes a variety of modifications that lead to nitrate
modifications has been recently proposed (22). Intermittent administration also
as been associated with induction of preconditioning. EC  endothelial cell;nonin
these
tion h
es.ramework for these drugs: acute nitroglycerin administra-
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uantities of oxygen free radicals, leads to the induction of
everal genes that cause anti-ischemic protection, resulting
n a phenotype similar to ischemic preconditioning
9,10,13). At the same time, the accumulation of these free
adical species over prolonged periods of time, as occurs
uring chronic nitrate therapy, has the potential to cause the
egative effects described earlier (1,2). Taken together,
hese lines of evidence suggest that nitrate-induced oxy-
en free radical production seems to explain both of the
cutely protective—but chronically deleterious—effects of
hese drugs.
The importance of nitrate-induced modifications in vas-
ular homeostasis should be seen in the context of their
linical effects, because they provide a mechanistic back-
round for: 1) the preconditioning mimetic, protective
roperties of nitrates against both demand-induced and
ow-flow myocardial ischemia; 2) the development of nitrate
olerance; and 3) the adverse effects on endothelial and
ascular function induced by prolonged nitrate treatment.
his latter consideration serves to emphasize that there is
cant evidence concerning the long-term clinical outcome of
itrate therapy. In the setting of stable angina pectoris, the
ocus of clinical research has been on how to prevent
olerance, and the largest studies of organic nitrates were
Figure 2 The Mechanism of the Dichotomous Biological Effects
When administered acutely, nitroglycerin is biotransformed in the mitochondrial ma
(NOx). At the same time, nitroglycerin causes uncoupling of the mitochondrial resp
a cascade that results in a phenotypic protection that is similar to ischemic preco
seems to have a critical role in the cascade that leads to nitrate preconditioning.
ROS production), does not cause preconditioning (23). On chronic administration,
rebound ischemia, endothelial and autonomic dysfunction, and oxidation of a critic
and nitrate tolerance. GTN  nitroglycerin; ISMN  isosorbide mononitrate.nderpowered for outcome data, all involving small patient uopulations with follow-up periods of only a few weeks
8,14,15). Studies in post-infarction patients, although
arger than those performed in chronic angina, have in-
olved follow-up periods too short to assess the true clinical
mpact of nitrate-induced endothelial dysfunction, auto-
omic impairment, and preconditioning: 6 weeks for the
ISSI (Gruppo Italiano Studio Sopravvivenza Infarto)-3
nd 4 weeks for the ISIS (International Study of Infarct
urvival)-4 trial (16,17). Emphasizing the need for data
egarding the outcome of chronic nitrate therapy, the only 2
andomized studies available with a treatment period longer
han 12 months did show that continuous nitrate therapy
ncreases the incidence of cardiac events (18) and that a
rend in the same direction is observed after intermittent
dministration (19), but these results cannot be considered
onclusive in the absence of a double-blind, placebo-
ontrolled design.
The previously discussed considerations emphasize the
eed for 2 areas of transitional research. First, there has
ever been a large-scale, double-blind, placebo-controlled,
andomized trial with a treatment period long enough to
ddress the issue of either efficacy or safety in patients with
table coronary artery disease. Clinicians should be aware
hat there is biological plausibility, founded in human data,
o warrant these studies (or at least, to warrant caution in the
itrates
the aldehyde dehydrogenase (ALDH) to release a nitric oxide–related species
chain and a burst of oxygen free radicals (ROS). Acutely, nitroglycerin activates
ing. The sudden increased bioavailability of nitric oxide and oxygen free radicals
, isosorbide mononitrate, which has an extramitochondrial bioactivation (and
-induced ROS production causes a number of adverse effects, which include
l group in the active site of ALDH, resulting in impaired nitrate biotransformationof N
trix by
iratory
ndition
Of note
nitrate
al thiose of nitrates). By contrast, evidence exists that these
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Chronic Therapy With Organic Nitrates July 22, 2008:251–4oxic phenomena might be offset by the use of drugs that
ave antioxidant properties or that prevent nitrate-induced
eactive oxygen species production. For instance, in patients
ith chronic heart failure, the benefit of isosorbide dinitrate
ombined with hydralazine is clear (20,21). The use of these
rugs should be considered when prescribing nitrates. The
econd area that should be explored is whether the ability of
itrates to protect from ischemia and reperfusion injury can
e turned into a long-term protection, in a form of chronic
harmacologic preconditioning. While it is accepted that
ree radical–based mechanisms underlie aspects of cardio-
ascular protection and disease, the observation that organic
itrates modify production and regulatory functions of these
lusive mediators provides a unique opportunity to explore
reviously unanticipated approaches to the utilization of
hese drugs.
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